Cargando…
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Invasive fungal infections are associated with significant morbidity and mortality, and their management is restricted to a variety of agents from five established classes of antifungal medication. In practice, existing antifungal agents are often constrained by dose-limiting toxicities, drug intera...
Autores principales: | Gintjee, Thomas J., Donnelley, Monica A., Thompson, George R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151215/ https://www.ncbi.nlm.nih.gov/pubmed/32106450 http://dx.doi.org/10.3390/jof6010028 |
Ejemplares similares
-
Antifungal Pipeline
por: McCarty, Todd Patrick, et al.
Publicado: (2021) -
Antifungal resistance, combinations and pipeline: oh my!
por: Stover, Kayla R, et al.
Publicado: (2023) -
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
por: Treviño-Rangel, Rogelio de J., et al.
Publicado: (2022) -
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021) -
Editorial: Antifungal Pipeline: Build It Strong; Build It Better!
por: Perfect, John R., et al.
Publicado: (2022)